Sam Brusco, Associate Editor04.06.22
STAAR Surgical has achieved the first implants of its EVO Visian Implantable Collamer lens (ICL) in the U.S. Further EVO ICL procedures have or will happen in California, Colorado, Missouri, Texas, and Utah in the coming days.
One of the first EVO ICL patients in the U.S. was a female in her 30s with myopia and astigmatism who previously used monthly disposable contact lenses and glasses. The Toric lens corrects myopia and astigmatism, and the bilateral EVO implant procedure took about seven to eight minutes for each eye.
STAAR also revealed its agenda of meetings and presentations for this month’s upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.
“We are thrilled to begin commercialization of our EVO lenses in the U.S. and announce milestone first implants just days after product approval,” Caren Mason, president and CEO of STAAR Surgical told the press. “The U.S. is a very important market for STAAR as it represents over 20% of global refractive procedures. U.S. surgeon enthusiasm is at an all-time high ahead of the ASCRS annual meeting later this month. We look forward to a strong and exciting showcasing of EVO ICL presentations and events at ASCRS and anticipate certifying hundreds of U.S. surgeons on EVO ICL implantation during the second quarter of 2022.”
STAAR’s EVO lenses earned U.S. Food and Drug Administration (FDA) approval at the end of March.
One of the first EVO ICL patients in the U.S. was a female in her 30s with myopia and astigmatism who previously used monthly disposable contact lenses and glasses. The Toric lens corrects myopia and astigmatism, and the bilateral EVO implant procedure took about seven to eight minutes for each eye.
STAAR also revealed its agenda of meetings and presentations for this month’s upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.
“We are thrilled to begin commercialization of our EVO lenses in the U.S. and announce milestone first implants just days after product approval,” Caren Mason, president and CEO of STAAR Surgical told the press. “The U.S. is a very important market for STAAR as it represents over 20% of global refractive procedures. U.S. surgeon enthusiasm is at an all-time high ahead of the ASCRS annual meeting later this month. We look forward to a strong and exciting showcasing of EVO ICL presentations and events at ASCRS and anticipate certifying hundreds of U.S. surgeons on EVO ICL implantation during the second quarter of 2022.”
STAAR’s EVO lenses earned U.S. Food and Drug Administration (FDA) approval at the end of March.